Is there a higher risk of respiratory depression in opioid-nave palliative care patients during symptomatic therapy of dyspnea with strong opioids?

Journal of Palliative Medicine

Volumn 11, Issue 2, 2008, Pages 204-216

  Clemens, Katri Elina ^a   Quednau, Ines ^b   Klaschik, Eberhard ^b  

^a UNIVERSITY OF BONN   (Germany)

^b Center for Palliative Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE;

ADULT; AGED; ARTICLE; BREATHING RATE; CARBON DIOXIDE TENSION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; PAIN; PALLIATIVE THERAPY; PROSPECTIVE STUDY; RECORDING; RESPIRATION DEPRESSION; RISK ASSESSMENT; TRANSCUTANEOUS CARBON DIOXIDE MONITORING;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CARBON DIOXIDE; DRUG THERAPY; DYSPNEA; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTICS; NEOPLASMS; OXIMETRY; OXYGEN; PALLIATIVE CARE; PREVALENCE; PROSPECTIVE STUDIES; RESPIRATORY INSUFFICIENCY; RISK FACTORS;

EID: 40649099659     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2007.0131     Document Type: Article

References (32)

1. Klaschik E: Dyspnoe. In: Husebo S, Klaschik E: Palliativmedizin. Aktualisierte, 4. Auflage. Berlin/Heidelberg/New York, Springer: 2006, pp. 276-279.
2. Heyse-Moore LH, Ross V, Mullee MA: How much of a problem is dyspnoea in advanced cancer? Palliat Med 1991;5:20-26
3. Frost JJ, Wagner HN Jr, Dannals RF, Ravert HT, Links JM, Wilson AA, Burns HD, Wong DF, McPherson RW, Rosenbaum AE: Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr 1985;9:231-236
4. Cohen RM, Carson RE, Channing M, Nordhal T, Gross M, Hanck-Newman A, Simpson H, Finn RD, Pert C, Rice K, Blasberg R, Larson SH: F-18-Cyclofoxy PET imaging in man. J Nucl Med 1988;29:796.
5. Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfield DR: BOLD fMRI densifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 2002;88:1500-1511.
6. Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L: Breathlessness in humans activates insular cortex. Neuroreport 2000;11:2117-2120.
7. Brannan S, Liotti M, Egan G, Shade R, Madden L, Robillard R, Abplanalp B, Stofer K, Denton D, Fox PT: Neuroimaging of cerebral activations and deactivations associated with hypercapnia and hunger for air. Proc Natl Acad Sci USA 2001;98:2029-2034.
8. Liotti M, Brannan S, Egan G, Shade R, Madden L, Abplanalp B, Robillard R, Lancaster J, Zamarripa FE, Fox PT, Denton D: Brain responses associated with consciouness of breathlessness (air hunger). Proc Natl Acad Sci USA 2001;98:2035-2040.
9. Parsons LM, Egan G, Liotti M, Brannan S, Denton D, Shade R, Robillard R, Madden L, Abplanalp B, Fox PT: Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air. Proc natl Acad Sci USA 2001;98:2041-2046.
10. Pfeiffer C, Poline JB, Thivard L, Aubier M, Samson Y: Neural Substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med 2001;163:951-957.
11. Gaytan SP, Pasaron R: Connections of the rostral ventral respiratory neuronal cell group: an anterograde and retrograde tracing study in the rat. Brain Res Bull 1998;47:625-642.
12. Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson PA, Coats AJ: Effects of dihydrocodeine on chemosensitivity and excercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997;29:147-152.
13. Williams SG, Wright DJ, Marshall P, Reese A, Tzeng BH, Coats AJ, Tan LB: Safety and potential benefits of low dose dia morphine during exercise in patients with chronic heart failure. Heart 2003;89:1085-1086.
14. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ: Morphine for the relief of breathlessness in patients in chronic heart failure. A pilot study. Eur J Heart Fail 2002;4:753-756.
15. de Conno F, Spoldi E, Caraceni A, Ventafridda V: Does pharmacological treatment affect the sensation of breathlessness in terminal cancer patients? Palliat Med 1991;5:237-243.
16. Bruera E, MacEachern T, Ripamonti C, Hanson J: Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993;119:906-907.
17. Allard P, Lamontagne C, Bernard P, Tremblay C: How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 1999;17:256-265.
18. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS; GOLD Scientific Committee: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respiratory Care 2001;46:798-825.
19. Ko S, Goldstein DH, VenDenKerkhof EG: Definitions of "respiratory depression" with intrathecal morphine postoperative analgesia: A review of the literature. Can J Anaesth 2003;50:679-688.
20. Shapiro A, Zohar E, Zaslansky R, Shabat S, Fredman B: The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth 2005;17:537-542.
21. Edwards MJ: Opioids and benzodiazepines appear paradoxically to delay inevitable death after ventilator withdrawal. J Palliat Care 2005;21:299-302.
22. Clemens KE, Klaschik E: Symptomatic therapy of dyspnoea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage 2007;33:473-481.
23. Bouillon T, Bruhn J, Roepcke H, Hoeft A: Opioid-induced respiratory depression is associated with increased tidal volume variability. Eur J Anaesthesiol 2003;20:127-133.
24. Barbour SJ, Vandebeek CA, Ansermino JM: Increased tidal volume variability in children is a better marker of opioid-induced respiratory depression than decreased respiratory rate. J Clin Monit Comput 2004;18:171-178.
25. Thorns A, Sykes N: Opioid use in last week of life and implications for end-of-life decision making. Lancet 2000;3556:398-399.
26. Bercovitch M, Waller A, Adunsky A: High-dose morphine use in the hospice setting. Cancer 1999;86:871-877.
27. Higginson I, Mc Carthy M: Measuring symptoms in terminal cancer care: Are pain and dyspnoea controlled? J R Soc Med 1989;82:264-267.
28. Erkut ZE, Klooker T, Endert E, Huitinga I, Swaab DF: Stress of dying is not suppressed by high-dose morphine or by dementia. Neuropsychopharmacology 2004;29:152-157.
29. Rosner V, Hannhart B, Chabot F, Polu JM: Validity of transcutaneous oxygen/carbon dioxide pressure measurement in the monitoring of mechanical ventilation in stable chronic respiratory failure. Eur Respir J 1999;13:1044-1047.
30. Hanly PJ: Transcutaneous monitoring of carbon dioxide tension. In: Tobin MJ (ed): Principles and Practice of Intensive Care Monitoring. New York: McGraw-Hill 1998, pp. 401-414.
31. Eberhard P, Gisiger PA, Gardaz JP Spahn DR: Combining transcutaneous blood gas measurement and pulse oximetry. Anesth Analg 2002;94(Suppl):S76-S80.
32. Cuvelier A, Grigorin B, Molano LC, Muir JF: Limitations of transcutaneous carbon dioxide measurements for assessing long-term mechanical ventilation. Chest 2005;127:1744-1748.